ENLV
Price
$1.08
Change
+$0.01 (+0.93%)
Updated
Oct 27 closing price
Capitalization
25.87M
34 days until earnings call
Intraday Buy/Sell Signals
FATE
Price
$1.55
Change
-$0.10 (-6.06%)
Updated
Oct 27 closing price
Capitalization
190.29M
2 days until earnings call
Intraday Buy/Sell Signals
Interact to see
Advertisement

ENLV vs FATE

Header iconENLV vs FATE Comparison
Open Charts ENLV vs FATEBanner chart's image
Enlivex Therapeutics
Price$1.08
Change+$0.01 (+0.93%)
Volume$85.84K
Capitalization25.87M
Fate Therapeutics
Price$1.55
Change-$0.10 (-6.06%)
Volume$8.62M
Capitalization190.29M
ENLV vs FATE Comparison Chart in %
ENLV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
FATE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ENLV vs. FATE commentary
Oct 28, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ENLV is a Hold and FATE is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 28, 2025
Stock price -- (ENLV: $1.08 vs. FATE: $1.55)
Brand notoriety: ENLV and FATE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ENLV: 42% vs. FATE: 368%
Market capitalization -- ENLV: $25.87M vs. FATE: $190.29M
ENLV [@Biotechnology] is valued at $25.87M. FATE’s [@Biotechnology] market capitalization is $190.29M. The market cap for tickers in the [@Biotechnology] industry ranges from $108.04B to $0. The average market capitalization across the [@Biotechnology] industry is $2.04B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ENLV’s FA Score shows that 1 FA rating(s) are green whileFATE’s FA Score has 1 green FA rating(s).

  • ENLV’s FA Score: 1 green, 4 red.
  • FATE’s FA Score: 1 green, 4 red.
According to our system of comparison, FATE is a better buy in the long-term than ENLV.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ENLV’s TA Score shows that 5 TA indicator(s) are bullish while FATE’s TA Score has 6 bullish TA indicator(s).

  • ENLV’s TA Score: 5 bullish, 6 bearish.
  • FATE’s TA Score: 6 bullish, 5 bearish.
According to our system of comparison, FATE is a better buy in the short-term than ENLV.

Price Growth

ENLV (@Biotechnology) experienced а +1.89% price change this week, while FATE (@Biotechnology) price change was +0.65% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.69%. For the same industry, the average monthly price growth was +11.04%, and the average quarterly price growth was +64.46%.

Reported Earning Dates

ENLV is expected to report earnings on Dec 01, 2025.

FATE is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Biotechnology (-0.69% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
FATE($190M) has a higher market cap than ENLV($25.9M). FATE YTD gains are higher at: -6.061 vs. ENLV (-7.692). ENLV has higher annual earnings (EBITDA): -14.21M vs. FATE (-161.6M). FATE has more cash in the bank: 223M vs. ENLV (19.5M). ENLV has less debt than FATE: ENLV (480K) vs FATE (81.3M). FATE has higher revenues than ENLV: FATE (8.47M) vs ENLV (0).
ENLVFATEENLV / FATE
Capitalization25.9M190M14%
EBITDA-14.21M-161.6M9%
Gain YTD-7.692-6.061127%
P/E RatioN/AN/A-
Revenue08.47M-
Total Cash19.5M223M9%
Total Debt480K81.3M1%
FUNDAMENTALS RATINGS
ENLV vs FATE: Fundamental Ratings
ENLV
FATE
OUTLOOK RATING
1..100
7224
VALUATION
overvalued / fair valued / undervalued
1..100
14
Undervalued
15
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9898
PRICE GROWTH RATING
1..100
6138
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ENLV's Valuation (14) in the Medical Specialties industry is in the same range as FATE (15) in the Biotechnology industry. This means that ENLV’s stock grew similarly to FATE’s over the last 12 months.

ENLV's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as FATE (100) in the Biotechnology industry. This means that ENLV’s stock grew similarly to FATE’s over the last 12 months.

ENLV's SMR Rating (98) in the Medical Specialties industry is in the same range as FATE (98) in the Biotechnology industry. This means that ENLV’s stock grew similarly to FATE’s over the last 12 months.

FATE's Price Growth Rating (38) in the Biotechnology industry is in the same range as ENLV (61) in the Medical Specialties industry. This means that FATE’s stock grew similarly to ENLV’s over the last 12 months.

FATE's P/E Growth Rating (100) in the Biotechnology industry is in the same range as ENLV (100) in the Medical Specialties industry. This means that FATE’s stock grew similarly to ENLV’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ENLVFATE
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
79%
Bearish Trend 1 day ago
90%
Momentum
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
81%
MACD
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
73%
Bullish Trend 1 day ago
82%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
75%
Bullish Trend 1 day ago
82%
Advances
ODDS (%)
Bullish Trend 1 day ago
75%
Bullish Trend 4 days ago
84%
Declines
ODDS (%)
Bearish Trend 5 days ago
88%
Bearish Trend 6 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bullish Trend 1 day ago
61%
Bullish Trend 1 day ago
87%
View a ticker or compare two or three
Interact to see
Advertisement
ENLV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
FATE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
UMICF19.710.04
+0.21%
Umicore SA
HMLN188.250.25
+0.13%
Hamlin Bank & Trust Co. (Smethport, PA)
WTBFA585.00N/A
N/A
W.T.B. Financial Corp.
CKHGY116.00-0.20
-0.18%
Capitec Bank Holdings Ltd
ENZN0.06-0.01
-17.01%
Enzon Pharmaceuticals, Inc.